Trially AI Secures $4.7M to Revolutionize Clinical Trial Recruitment
September 24, 2025, 3:56 pm
Trially AI secured $4.7M in seed funding. This capital fuels its AI-first platform, tackling critical clinical trial recruitment delays. Its Margo AI solution leverages HIPAA-compliant LLMs to instantly match, connect, and enroll patients. This system cuts manual review time by 91%, boosts enrollment 2-6x, and achieves 95% screening accuracy. It addresses the $600K daily industry loss from recruitment failures. The funding will accelerate platform adoption across research sites, pharma, and CROs, speeding life-saving treatments to patients. Trially transforms an outdated process, offering efficiency and hope.
Kansas City-based Trially AI has completed a significant seed funding round. The company raised $4.7 million. This investment empowers its mission. Trially seeks to transform clinical trial recruitment. It uses advanced artificial intelligence. This shift is crucial for healthcare innovation.
Clinical trial recruitment faces severe challenges. It remains a persistent bottleneck. Studies indicate 86% of trials experience delays. Participant recruitment causes these setbacks. The pharmaceutical industry suffers immense losses. Over $600,000 is lost daily. These are direct results of recruitment failures. Patients also pay a heavy price. They await life-saving treatments for years. The traditional system is slow. It relies on manual chart reviews. It involves extensive cold calling. This process demands hundreds of hours. Trially AI offers a radical solution.
Trially AI emerged as an AI-first platform. It addresses core recruitment issues. The system is fully integrated. It uses HIPAA-compliant Large Language Model (LLM) agents. These agents safely analyze vast unstructured medical data. This capability is paramount. It allows instant patient matching. Patients are connected with relevant trials. The old, labor-intensive process vanishes. Instant enrollment opportunities arise.
At the heart of Trially's innovation is Margo. Margo is an agentic AI solution. It dramatically multiplies trial enrollment. Margo converts patient matches directly into participants. This conversion is a critical step. It solves a long-standing industry problem. Margo unifies three powerful tools. Each tool streamlines the recruitment pipeline.
First, Trially Match excels at data interpretation. It safely reads rich medical data. This includes complex patient histories. It then instantly matches patients to appropriate trials. Precision is key. Accurate matching reduces future complications. It ensures eligibility.
Next, Trially Connect initiates direct outreach. This agentic AI function is dynamic. It pre-screens matched patients. It engages potential candidates directly. Qualified candidates convert into enrollments. This step replaces manual communication. It accelerates participant onboarding. It optimizes engagement timing.
Finally, Trially Intelligence provides strategic foresight. It acts as a pipeline radar. This tool proactively alerts users. It identifies trials suitable for specific patient populations. It also delivers instant feasibility analytics. This intelligence allows sites to plan ahead. It maximizes their trial participation potential. It makes strategic decisions easier.
The impact of Trially's platform is substantial. Organizations report significant gains. They enroll two to six times more patients monthly. This applies even to complex trials. Screening accuracy is impressive. The platform achieves approximately 95% accuracy. This measures against strict eligibility criteria. It leads to a dramatic 73% reduction in screen failures. Better patient matching drives this success.
Efficiency improvements are widespread. Users spend 91% less time on manual chart reviews. This frees up valuable staff time. Teams can focus on critical patient care. They can pursue other vital tasks. A notable example highlights financial benefits. One site network saw a $4 million revenue increase. This occurred in just three months. This demonstrates immediate financial returns. The AI capabilities identify trial candidates rapidly. The platform finds ten times more candidates instantly. This underscores its transformative potential.
The recent seed funding round confirms Trially's promise. Flyover Capital led the investment. Other participants included Alpaca, Atria, Blu Ventures, Looking Glass Capital, Redbud, The Council, and Gaingels. This capital injection is strategic. It will accelerate the platform's adoption. Trially will expand its reach. This includes research sites, pharmaceutical sponsors, and Contract Research Organizations (CROs). Physician networks will also benefit.
Trially AI reshapes clinical research. It solves a decades-old problem. The platform leverages AI for precision. It improves efficiency and outcomes. It promises faster access to life-saving medicine. Patients benefit directly. The healthcare industry gains stability. Trially AI represents a pivotal advancement. It offers a new paradigm for trial enrollment.
Kansas City-based Trially AI has completed a significant seed funding round. The company raised $4.7 million. This investment empowers its mission. Trially seeks to transform clinical trial recruitment. It uses advanced artificial intelligence. This shift is crucial for healthcare innovation.
Clinical trial recruitment faces severe challenges. It remains a persistent bottleneck. Studies indicate 86% of trials experience delays. Participant recruitment causes these setbacks. The pharmaceutical industry suffers immense losses. Over $600,000 is lost daily. These are direct results of recruitment failures. Patients also pay a heavy price. They await life-saving treatments for years. The traditional system is slow. It relies on manual chart reviews. It involves extensive cold calling. This process demands hundreds of hours. Trially AI offers a radical solution.
Trially AI emerged as an AI-first platform. It addresses core recruitment issues. The system is fully integrated. It uses HIPAA-compliant Large Language Model (LLM) agents. These agents safely analyze vast unstructured medical data. This capability is paramount. It allows instant patient matching. Patients are connected with relevant trials. The old, labor-intensive process vanishes. Instant enrollment opportunities arise.
At the heart of Trially's innovation is Margo. Margo is an agentic AI solution. It dramatically multiplies trial enrollment. Margo converts patient matches directly into participants. This conversion is a critical step. It solves a long-standing industry problem. Margo unifies three powerful tools. Each tool streamlines the recruitment pipeline.
First, Trially Match excels at data interpretation. It safely reads rich medical data. This includes complex patient histories. It then instantly matches patients to appropriate trials. Precision is key. Accurate matching reduces future complications. It ensures eligibility.
Next, Trially Connect initiates direct outreach. This agentic AI function is dynamic. It pre-screens matched patients. It engages potential candidates directly. Qualified candidates convert into enrollments. This step replaces manual communication. It accelerates participant onboarding. It optimizes engagement timing.
Finally, Trially Intelligence provides strategic foresight. It acts as a pipeline radar. This tool proactively alerts users. It identifies trials suitable for specific patient populations. It also delivers instant feasibility analytics. This intelligence allows sites to plan ahead. It maximizes their trial participation potential. It makes strategic decisions easier.
The impact of Trially's platform is substantial. Organizations report significant gains. They enroll two to six times more patients monthly. This applies even to complex trials. Screening accuracy is impressive. The platform achieves approximately 95% accuracy. This measures against strict eligibility criteria. It leads to a dramatic 73% reduction in screen failures. Better patient matching drives this success.
Efficiency improvements are widespread. Users spend 91% less time on manual chart reviews. This frees up valuable staff time. Teams can focus on critical patient care. They can pursue other vital tasks. A notable example highlights financial benefits. One site network saw a $4 million revenue increase. This occurred in just three months. This demonstrates immediate financial returns. The AI capabilities identify trial candidates rapidly. The platform finds ten times more candidates instantly. This underscores its transformative potential.
The recent seed funding round confirms Trially's promise. Flyover Capital led the investment. Other participants included Alpaca, Atria, Blu Ventures, Looking Glass Capital, Redbud, The Council, and Gaingels. This capital injection is strategic. It will accelerate the platform's adoption. Trially will expand its reach. This includes research sites, pharmaceutical sponsors, and Contract Research Organizations (CROs). Physician networks will also benefit.
Trially AI reshapes clinical research. It solves a decades-old problem. The platform leverages AI for precision. It improves efficiency and outcomes. It promises faster access to life-saving medicine. Patients benefit directly. The healthcare industry gains stability. Trially AI represents a pivotal advancement. It offers a new paradigm for trial enrollment.